WG Health Archive                                                                 

WORKING GROUP HEALTH 

Tuesday, 11 July 2017 from 08:00 to 09:30 hrs  

“Digital Single Market and Healthcare: challenges and opportunities for data protection and a better use of health data”  

Speakers:

Michal BONI MEP, EPP/Poland, Member of the Committee on Civil Liberties, Justice and Home Affairs

Tapani PIHA, Head of Unit, Cross-border Healthcare and eHealth, DG SANTE, European Commission

Knut MAGER, Global Head Data Privacy, Novartis  

Wednesday, 7 December 2016 from 08:00 to 09:30 hrs

Room: Restaurant des Députés, Salon Privé

European Parliament, Brussels

“The Future of the single regulatory system of medicines: Towards better harmonization or increased fragmentation?”
 

Welcome and Chair: Karl von WOGAU, Secretary General of the Kangaroo Group

Speakers:

• Dennis HORGAN, Executive Director, European Alliance for Personalised Medicine (EAPM)
• Annika NOWAK, Member of the Cabinet of Commissioner Vytenis Andriukaitis
• Nathalie Moll, Secretary-General, EuropaBio

Brussels-Breakfast-Debate, Wednesday, 16 March 2016 from 8:00 to 9:30 hrs

“Transparent prices versus confidential agreements:

What’s best for patient access and sustainable healthcare?”

Introduction: Paul RÜBIG MEP, EVP/Austria, Member of the Committees on Industry, Research and Energy and Budgets

Presentation: Dermot GLYNN, Europe Economics, Author of the Study « External Reference Pricing – the case for transparency in pricing »

Panelists:

• Andrzej Jan RYS, Director, Health Systems, Medical Products and Innovation, DG SANTE

• David SAUNDERS, former Chief Executive of UK Competition Commission

• Erik MEINHARDT, Market Access Lead for Europe and Canada, MSD Menno AARNOUT, Executive Director, International Association of Mutual Benefits Societies (AIM)

Conclusion: Nicola BEDLINGTON, Secretary General of the European Patients' Forum (EPF)

With the completion of the Single Market being one of its key goals, inequalities in access to innovative medicines are of concern to the Kangaroo Group. The Dutch EU Council Presidency has called for greater transparency in how prices are set in its “Summary of Medicines Plan”. Health minister Edith Schippers furthermore argued that it was unfair that pharmaceutical companies knew the prices of their drugs in 28 EU Member States, but that health ministers could not exchange such information. The European Commission has recently published a study “Enhanced cross-country collaboration in the area of pharmaceutical product pricing” and is also in the process of developing, together with Member States, the EURIPID pricing database to help exchange information in the context of the Transparency Directive